Use of an animal model to evaluate anxiolytic effects of dietary supplementation with tilia tomentosa moench bud extracts

Anxiety disorders are common and complex psychiatric syndromes affecting a broad spectrum of patients. On top of that, we know that aging produces an increase in anxiety vulnerability and sedative consumption. Moreover, stress disorders frequently show a clear gender susceptibility. Currently, the approved pharmacological strategies have severe side effects such as hallucinations, addiction, suicide, insomnia, and loss of motor coordination. Dietary integration with supplements represents an intriguing strategy for improving the efficacy and the safety of synthetic anxiolytics. Accordingly, a recent article demonstrated that glyceric bud extracts from Tilia tomentosa Moench (TTBEs) exert effects that are consistent with anxiolytic activity. However, the effects of these compounds in vivo are unknown. To examine this question, we conducted behavioral analysis in mice. A total of 21 days of oral supplements (vehicle and TTBEs) were assessed by Light Dark and Hole Board tests in male and female mice (young, 3 months; old, 24 months). Interestingly, the principal component analysis revealed gender and age-specific behavioral modulations. Moreover, the diet integration with the botanicals did not modify the body weight gain and the daily intake of water. Our results support the use of TTBEs as dietary supplements for anxiolytic purposes and unveil age and gender-dependent responses

DIFFERENTIAL VIRAL SENSITIVITY TO PHOTOINACTIVATION BY HAEMATOPORPHYRIN AND HAEMATOPORPHYRIN DERIVATIVE

Etude de l'influence de l'haematoporphyrine (HP) et des dérivés de l'haematoporphyrine (HPD) sur la sensibilité virale à la photoinactivation. HPD a une action plus efficace sur l'inactivation virale un spectre d'action plus large et agit particulièrement sur le virus de la vaccine. Le fait que l'enveloppe virale puisse être une cible préférentielle pour les processus d'oxydation photodynamiques est discut

Routine separation of staphylococci from micrococci based on bacteriolytic activity production.

A new method is described by which separation of staphylococci from micrococci can be achieved in routine laboratory use. The basis of this method is that bacteriolytic activity is produced by staphylococci but not by micrococci

Inhibition of Herpes simplex virus-induced cytopathic effect by modified hen egg white lysozyme

Hen egg-white lysozyme and three of its basic derivatives obtained by chemical modification were tested for their activity in vitro against a wild strain of herpes simplex virus type 1. Marked inhibition of the cytopathic effect was exhibited by the three chemical derivatives and the heat-inactivated lysozyme, whereas the native enzyme displayed only modest anticytopathic activity. Enzymatic activity did not appear to be necessary for the antiherpes activity of the lysozyme compounds. Instead, other properties such as their basic nature seemed to be relevant to their antiherpes effectiveness in vitro. At the concentrations used, all compounds but one had no significant effect on cell viability and growth. Some of the compounds tested caused formation of deposits on the surface of the cells. Some correlation between deposit formation and antiherpes cytopathic activity was found. The antiherpes efficacy in vitro and toxicity of the modified lysozymes were compared with those of known antiviral agents. The lysozymes were less toxic than the reference antiviral agents, and some of them were also more activ

High-level potentiation of lysostaphin anti-staphylococcal activity by lysozyme.

The purpose of this study was to determine whether lysostaphin would enhance its anti-staphylococcal efficacy in combination with lysozyme. Minimum inhibitory concentrations (MICs) of lysostaphin and lysozyme were separately determined for 41 strains belonging to 10 different species of human staphylococci. Lysozyme was virtually inactive and showed MICs of 15 mg/ml. On the contrary, all strains were susceptible to lysostaphin and showed MICs ranging from 2.5 to 60 micrograms/ml for the different Staphylococcus species. When the MIC of lysostaphin was determined in media containing submultiples of the MIC of lysozyme, the values obtained were much lower. The reduction of the lysostaphin MIC ranged from 16- to 200-fold in the different species tested. In Staphylococcus aureus, in particular, the combination of lysostaphin with 1.5 mg of lysozyme per ml reduced the MIC of lysostaphin by 25-fold. The activities of two combinations of the two enzymes were evaluated: one combination was expected to be active on S. aureus only, and the other combination was expected to inhibit all Staphylococcus strains. The first combination (0.5 micrograms of lysostaphin plus 0.5 mg of lysozyme per ml) was inhibitory to all of the 84 S. aureus strains tested, whereas 137 of 151 strains of other Staphylococcus species were unaffected. On the contrary, all of the 235 Staphylococcus strains tested were inhibited by the second combination (4 micrograms of lysostaphin plus 5 mg of lysozyme per ml). The possible mechanisms of lysostaphin potentiation by lysozyme are considered, and the potential use of a lysostaphin-lysozyme combination for topical therapy of staphylococcal infections resistant to other antibiotics is discussed